PerpEquities

Zoetis Inc. (ZTS) cash flow statement

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · 14,500 employees · CEO Kristin C. Peck

Price
$82.11 -7.95%
Market cap
$33.9B
Enterprise value
$32.8B
Last report
Q3 '26 filed 2026-11-05
Next report
2027-02-11 EPS est. $1.29

In Q3 '26 Zoetis Inc. (ZTS) generated $824M of operating cash flow, invested $107M in capital expenditure and kept $717M of free cash flow. Over the last four quarters free cash flow was $2.28B.

Cash flow

Cash flowTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating
Net income$525M$599M$624M$692M$581M$631M$718M$721M$603M$601M$691M$591M
Depreciation & amortization$126M$126M$127M$121M$123M$119M$123M$124M$121M$119M$119M$119M
Stock-based compensation$17M$18M$19M$18M$19M$17M$22M$22M$22M$25M$26M$27M
Deferred income tax-$21M-$43M-$101M-$42M-$152M$19M-$7M-$16M-$48M$34M-$33M-$12M
Change in working capital$202M-$121M-$239M$360M$309M-$217M-$415M$54M$170M-$385M$142M$243M
Other non-cash items$48M$16M$72M-$198M$25M$18M$45M$33M$25M$7M-$290M-$144M
Operating cash flow$897M$595M$502M$951M$905M$587M$486M$938M$893M$401M$655M$824M
Investing
Capital expenditure-$198M-$140M-$132M-$167M-$216M-$149M-$178M-$133M-$161M-$110M-$117M-$107M
Acquisitions-$96M$1M-$8M-$1M$293M$0$0-$10M-$14M$0$0-$155M
Purchases of investments-$1M-$1M-$2M-$1M-$1M-$27M-$52M$73M$11M-$2M-$206M-$2M
Sales / maturities of investments-$11M$10M$11M-$10M$51M$0$0$0$0$16M-$5M-$11M
Other investing$96M-$1M-$1M$1M-$1M$1M-$17M-$90M-$2M$9M$28M$13M
Investing cash flow-$210M-$131M-$132M-$178M$126M-$175M-$247M-$160M-$166M-$87M-$300M-$262M
Financing
Net debt issued / repaid$1M$21M-$24M$0$0$0$0$484M$1.78B$0$0$0
Share buybacks-$235M-$339M-$533M-$433M-$553M-$443M-$338M-$394M-$2.06B-$606M-$584M-$500M
Dividends-$172M-$198M-$197M-$197M-$194M-$224M-$223M-$222M-$220M-$224M-$223M$0
Other financing (incl. tax on vested shares)$9M-$8M-$5M$2M$2M-$10M-$3M-$2M$1M-$10M-$6M-$499M
Financing cash flow-$397M-$524M-$763M-$628M-$745M-$677M-$564M-$134M-$495M-$840M-$813M-$718M
Summary
FX effect on cash-$3M-$6M-$8M-$5M-$13M-$1M$39M$5M-$4M$17M-$7M$13M
Net change in cash$287M-$66M-$401M$140M$273M-$266M-$286M$649M$228M-$509M-$465M-$143M
Free cash flow (OCF - capex)$699M$455M$370M$784M$689M$438M$308M$805M$732M$291M$538M$717M
Income taxes paid$168M$59M$422M$176M$235M$47M$428M$107M$133M$50M$380M$0
Interest paid$70M$68M$70M$67M$69M$68M$69M$88M$36M$109M$39M$0

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-06